. 2009 Spring;2(2):84–92.

Table 2.

Percentage of US Women Experiencing an Unintended Pregnancy During the First Year of Typical Use and the First Year of Perfect Use of Contraception and the Percentage Continuing Use at the End of the First Year

	Women Experiencing an Unintended Pregnancy Within the First Year of Use (%)
Method	Typical Use	Perfect Use	Women Continuing Use at 1 Year (%)
No method	85	85
Spermicides	29	18	42
Withdrawal	27	4	43
Periodic abstinence	25		51
Calendar		9
Ovulation method		3
Symptothermal		2
Postovulation		1
Cap
Parous women	32	26	46
Nulliparous women	16	9	57
Sponge
Parous women	32	20	46
Nulliparous women	16	9	57
Diaphragm	16	6	57
Condom
Female (Reality)	21	5	49
Male	15	2	53
Combined pill and minipill	8	0.3	68
Ortho Evra® patch	8	0.3	68
NuvaRing®	8	0.3	68
Depo-Provera®	3	0.3	56
Lunelle™	3	0.05	56
IUD
ParaGard® (copper T)	0.8	0.6	78
Mirena® (levonorgesterel-releasing intrauterine system)	0.1	0.1	81
Norplant® and Norplant-2®	0.05	0.05	84
Female sterilization	0.5	0.5	100
Male sterilization	0.15	0.10	100

Reality, Female Health Company, UK; Ortho Evra, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ; NuvaRing, Organon USA Inc., Roseland, NJ; Depo-Provera, Pfizer Inc, New York, NY; Lunelle, Pharmacia Corporation, Peapack, NJ; ParaGard, Duramed Pharmaceuticals, Inc., Pomona, NY; Mirena, Bayer Healthcare Pharmaceuticals, Montville, NJ; Norplant and Norplant-2, Wyeth Pharmaceuticals Inc., Philadelphia, PA.